Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
The Greater Cannabis Company, Inc. (GCAN)
USD0.25
+0.00 (+0.00%)
US OTC Healthcare Medical - Pharmaceuticals
Address
2833 Smith Avenue 21209
Baltimore, MD, US
Baltimore, MD, US
CEO
Aitan Zacharin
Website
gcanrx.com
IPO
2018-09-18
CIK 1695473 ISIN US3916572023
Description
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.25
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.4K
Beta
0.38
Float Shares
585.00
Free Float %
6.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +24.14% | +24.14% | -1.10% | -27.24% | +242.86% | +140.00% | +51,328.57% | +35,900.00% | +2,164.15% | +28.57% | +28.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.25
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-6,135.89
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-199,900.0% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'26: +26.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+2.5% Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.80× Q1'26: -2.01× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
372.0K
Cash buys
—
Cash sales
2.00
Net activity
-371,958
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-04 | Sapir LLC | 10% Owner | A-Award | A | Common Stock | 100,000,000 | 0.00 | 100.0K | 0 | I | ↗ |
| 2019-12-02 | Anderson Jimmy Wayne | 10% Owner | S-Sale | D | Common Stock | 176,878 | 0.03 | 5.4K | 6,275,534 | — | ↗ |
| 2019-11-27 | Anderson Jimmy Wayne | 10% Owner | S-Sale | D | Common Stock | 195,080 | 0.05 | 9.0K | 6,452,412 | — | ↗ |
| 2019-01-01 | Anderson Jimmy Wayne | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,019,016 | — | ↗ |
| 2018-07-31 | ZACHARIN AITAN | Director / Officer / 10% Owner | — | — | Series A Preferred Stock | 74,166,650 | 0.00 | — | 0 | D | ↗ |
| 2007-10-30 | DEMEDIO DAVID M | Director | — | D | Stock Options | 225,000 | 0.41 | 92.3K | 0 | — | ↗ |
| 2007-05-17 | ORLEV CHAIME | Officer | A-Award | A | Option | 300,000 | 0.61 | 183.0K | 300,000 | — | ↗ |
| 2007-05-17 | LEVI SHMUEL | Director | A-Award | A | Option | 150,000 | 0.61 | 91.5K | 150,000 | — | ↗ |
| 2007-02-23 | ORLEV CHAIME | Officer | A-Award | A | Options | 0 | 0.53 | — | 250,000 | — | ↗ |
| 2007-02-23 | LEVI SHMUEL | Director | A-Award | A | Options | 75,000 | 0.53 | 39.8K | 75,000 | — | ↗ |
| 2007-02-23 | KATZ STEVEN | Director | A-Award | A | Options | 1,150,000 | 0.53 | 609.5K | 1,150,000 | — | ↗ |
| 2006-11-07 | KATZ STEVEN | Director | A-Award | A | Options | 150,000 | 0.45 | 67.5K | 150,000 | — | ↗ |
| 2006-11-06 | KATZ STEVEN | Director | — | D | Stock Options | 150,000 | 0.45 | 67.5K | 0 | — | ↗ |
| 2006-05-04 | LEVI SHMUEL | Director | A-Award | A | Options | 100,000 | 1.29 | 129.0K | 150,000 | — | ↗ |
| 2005-10-06 | ORLEV CHAIME | Officer | — | D | Stock Option | 350,000 | 0.93 | 325.5K | 0 | — | ↗ |
| 2005-06-21 | LEVI SHMUEL | Director | A-Award | A | Options | 50,000 | 1.15 | 57.5K | 50,000 | — | ↗ |
| 2004-08-18 | LEVI SHMUEL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
944.9K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2022-11-21 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aitan Zacharin | Chairman, President, Chief Executive Officer, Acting Chief Financial Officer & Treasurer | 120.0K | male |
| Adi Aran | Chief Scientific Advisor | — | — |
| Motti Stenge | Chief Operating Officer | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GCAN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
